AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38907052 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-diameter tissue level implant in T2DM patients
Number of subjects: 26
Study 38907052 — intervention group
Group type: COMPARATOR
Intervention: Narrow-diameter tissue level implant in normoglycemic patients
Number of subjects: 26
Study 38907104 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (starting dose 160 mg)
Number of subjects: 0
Study 38907104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38907106 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine (PE) infusion at 15-20 mikrg/min adjusted until preload was restored (SVV < 12%)
Number of subjects: 20
Study 38907120 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytosorb® (CS) for myoglobin elimination
Number of subjects: 20
Study 38907138 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-melanoma skin cancers (NMSC)
Number of subjects: 200
Study 38907138 — intervention group
Group type: EXPERIMENTAL
Intervention: Benign tumors (BT)
Number of subjects: 200
Study 38907138 — intervention group
Group type: COMPARATOR
Intervention: Control group (no NMSC or BT)
Number of subjects: 200
Study 38907138 — intervention group
Group type: EXPERIMENTAL
Intervention: Hematopoietic cell transplantation (HCT)
Number of subjects: 200
Study 38907159 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab, dabrafenib and trametinib
Number of subjects: 0
Study 38907160 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 23
Study 38907175 — intervention group
Group type: COMPARATOR
Intervention: Eliapixant (25 mg, 75 mg, and 150 mg) administered as an oral amorphous solid dispersion immediate-release tablet.
Number of subjects: 36
Study 38907175 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group).
Number of subjects: 36
Study 38907254 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care involving community pharmacists
Number of subjects: 175
Study 38907254 — intervention group
Group type: COMPARATOR
Intervention: Usual care without community pharmacist involvement
Number of subjects: 175
Study 38907254 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 175
Study 38907310 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter swimming
Number of subjects: 23
Study 38907310 — intervention group
Group type: COMPARATOR
Intervention: Control group (sedentary males)
Number of subjects: 23
Study 38907320 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive (ministernotomy)
Number of subjects: 100
Study 38907320 — intervention group
Group type: COMPARATOR
Intervention: Full sternotomy
Number of subjects: 100
Study 38907331 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Implementation Feedback (RIF) report
Number of subjects: 125
Study 38907331 — intervention group
Group type: EXPERIMENTAL
Intervention: RIF report findings
Number of subjects: 125
Study 38907342 — intervention group
Group type: EXPERIMENTAL
Intervention: Selumetinib treatment
Number of subjects: 4
Study 38907380 — intervention group
Group type: EXPERIMENTAL
Intervention: VR-guided meditation
Number of subjects: 10
Study 38907679 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPro-UK 35 mg (15 mg bolus + 20 mg infusion/30 min)
Number of subjects: 1552
Study 38907679 — intervention group
Group type: COMPARATOR
Intervention: rt-PA 0.9 mg/kg (10% bolus + 90% infusion/1 h)
Number of subjects: 1552
Study 38907679 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPro-UK 35 mg
Number of subjects: 1552
Study 38907784 — intervention group
Group type: EXPERIMENTAL
Intervention: Participative problem-solving intervention aimed to reduce sick-leave
Number of subjects: 197
Study 38907784 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU) involving any kind of work-directed interventions
Number of subjects: 197
Study 38906616 — intervention group
Group type: EXPERIMENTAL
Intervention: GSU-Pulmonary Score (developed from 13 candidate predictor variables)
Number of subjects: 86231
Study 38906616 — intervention group
Group type: EXPERIMENTAL
Intervention: GSU-Pulmonary Score
Number of subjects: 86231
Study 38906616 — intervention group
Group type: EXPERIMENTAL
Intervention: LASSO regression
Number of subjects: 86231
Study 38906616 — intervention group
Group type: EXPERIMENTAL
Intervention: XGBoost
Number of subjects: 86231
Study 38907877 — intervention group
Group type: EXPERIMENTAL
Intervention: Deucravacitinib 6 mg once daily
Number of subjects: 500
Study 38907877 — intervention group
Group type: COMPARATOR
Intervention: Apremilast 30 mg twice daily
Number of subjects: 500
Study 38907886 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferumoxtran-10-enhanced 3-T MRI
Number of subjects: 27
Study 38907935 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin efsitora alfa (efsitora)
Number of subjects: 54
Study 38907935 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (glargine)
Number of subjects: 54
Study 38908553 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelium-off CXL protocol using a UV-A medical device with theranostic software, 0.22% riboflavin for 15 minutes, 9 minutes of UV-A irradiance at 10 mW/cm²
Number of subjects: 50
Study 38908553 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelium-on CXL protocol using a UV-A medical device with theranostic software, 0.22% riboflavin for 20 minutes, 9 minutes of UV-A irradiance at 10 mW/cm²
Number of subjects: 50
Study 38908733 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT) at weeks 0, 2, 4, and 8; n = 30
Number of subjects: 60
Study 38908733 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation (FMT)
Number of subjects: 60
Study 38908733 — intervention group
Group type: COMPARATOR
Intervention: Control group; n = 30
Number of subjects: 60
Study 38908840 — intervention group
Group type: EXPERIMENTAL
Intervention: Manas por Manas intervention
Number of subjects: 400
Study 38908840 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 400
Study 38908841 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO intervention (responsive web application for weekly symptom reporting with proactive follow-up by nurses for 6 weeks)
Number of subjects: 50
Study 38908841 — intervention group
Group type: EXPERIMENTAL
Intervention: ePRO intervention
Number of subjects: 50
Study 38908843 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-Check health and well-being check-up programme involving screening, on-the-spot care, and referral.
Number of subjects: 6000
Study 38908843 — intervention group
Group type: EXPERIMENTAL
Intervention: Y-Check health and well-being check-up programme.
Number of subjects: 6000
Study 38908842 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month supervised strength exercise intervention
Number of subjects: 120
Study 38908842 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 38908848 — intervention group
Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 98
Study 38908848 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 98
Study 38909093 — intervention group
Group type: EXPERIMENTAL
Intervention: Horticultural therapy alongside usual care
Number of subjects: 211
Study 38909093 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 211
Study 38909144 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg/day for approximately 80% of patients, 15 mg/day for the remaining patients)
Number of subjects: 5717
Study 38909157 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest shield (with aluminum foil)
Number of subjects: 140
Study 38909157 — intervention group
Group type: COMPARATOR
Intervention: Sham shield (without aluminum foil)
Number of subjects: 140
Study 38909189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartarase dentifrice (used twice daily)
Number of subjects: 40
Study 38909189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tartarase dentifrice (used with dental tray for 30 min, then brushed again once daily)
Number of subjects: 40
Study 38909189 — intervention group
Group type: COMPARATOR
Intervention: Crest Cavity Protection (control dentifrice)
Number of subjects: 40
Study 38909201 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric intermittent hypoxia (fraction of inspired oxygen 0.16 for 5 min interspersed with 5 min normoxia), 45 min, 3 times a week for 4 weeks
Number of subjects: 40
Study 38909201 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric intermittent hypoxia
Number of subjects: 40
Study 38909215 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnering to Achieve School Success (PASS)
Number of subjects: 300
Study 38909215 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 300
Study 38909229 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photobiomodulation
Number of subjects: 64
Study 38909229 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthetic gel
Number of subjects: 64
Study 38909352 — intervention group
Group type: EXPERIMENTAL
Intervention: eTEP
Number of subjects: 60
Study 38909352 — intervention group
Group type: COMPARATOR
Intervention: RS
Number of subjects: 60
Study 38909349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phenylbutyrate-tauroursodeoxycholic acid (PB-TUDCA)
Number of subjects: 0
Study 38909671 — intervention group
Group type: EXPERIMENTAL
Intervention: Microdissection testicular sperm extraction (micro-TESE)
Number of subjects: 616
Study 38909671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-SR hormonal stimulation
Number of subjects: 616
Study 38909671 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline follicle-stimulating hormone levels
Number of subjects: 616
Study 38909671 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of clinical varicocele
Number of subjects: 616
Study 38909671 — intervention group
Group type: EXPERIMENTAL
Intervention: History of previous varicocelectomy
Number of subjects: 616
Study 38909671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-micro-TESE testosterone levels
Number of subjects: 616
Study 38909671 — intervention group
Group type: EXPERIMENTAL
Intervention: Delta T (absolute increase in T levels from baseline)
Number of subjects: 616
Study 38909712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung transplantation (LT)
Number of subjects: 31
Study 38909740 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 25 mg weekly oral
Number of subjects: 93
Study 38909740 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 1.5 g twice daily oral
Number of subjects: 93
Study 38909877 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis treatment
Number of subjects: 1441
Study 38909877 — intervention group
Group type: COMPARATOR
Intervention: Tafamidis untreated
Number of subjects: 1441
Study 38909994 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab
Number of subjects: 40
Study 38909998 — intervention group
Group type: EXPERIMENTAL
Intervention: ChitoCare gel
Number of subjects: 42
Study 38909998 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 42
Study 38910002 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal application of Vagifem 30 µg once a day for 14 days prior to colposcopy
Number of subjects: 150
Study 38910002 — intervention group
Group type: COMPARATOR
Intervention: Placebo once a day for 14 days prior to colposcopy
Number of subjects: 150
Study 38910002 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal application of Vagifem 30 µg
Number of subjects: 150
Study 38910002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 38910112 — intervention group
Group type: EXPERIMENTAL
Intervention: Recorded maternal voice played into the infant incubator between 15 and 21 days of life
Number of subjects: 40
Study 38910112 — intervention group
Group type: COMPARATOR
Intervention: Control group (no recorded maternal voice intervention)
Number of subjects: 40
Study 38910197 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.1-mm cryoprobe
Number of subjects: 224
Study 38910197 — intervention group
Group type: COMPARATOR
Intervention: 1.9-mm cryoprobe
Number of subjects: 224
Study 38910234 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support intervention involving an informal caregiver, nurse consultations, and motivational text messages over 6 months.
Number of subjects: 464
Study 38910557 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-item Kansas City Cardiomyopathy Questionnaire (baseline assessment)
Number of subjects: 162
Study 38910557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oberst Caregiving Burden Scale (OCBS-time)
Number of subjects: 162
Study 38910557 — intervention group
Group type: EXPERIMENTAL
Intervention: Oberst Caregiving Burden Scale (OCBS-difficulty)
Number of subjects: 162
Study 38910596 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived social isolation
Number of subjects: 163
Study 38910596 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience
Number of subjects: 163
Study 38910596 — intervention group
Group type: EXPERIMENTAL
Intervention: Promotion of social connection and resilience
Number of subjects: 163
Study 38910601 — intervention group
Group type: EXPERIMENTAL
Intervention: Aesthetic evaluation scale in patients with systemic sclerosis
Number of subjects: 88
Study 38910891 — intervention group
Group type: EXPERIMENTAL
Intervention: Anaprazole
Number of subjects: 0
Study 38910891 — intervention group
Group type: COMPARATOR
Intervention: Ilaprazole
Number of subjects: 0
Study 38910914 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm-based screening program
Number of subjects: 769
Study 38910914 — intervention group
Group type: COMPARATOR
Intervention: Reference group (non-obese)
Number of subjects: 769
Study 38910942 — intervention group
Group type: EXPERIMENTAL
Intervention: High-risk aMCI group
Number of subjects: 176
Study 38910942 — intervention group
Group type: COMPARATOR
Intervention: Low-risk aMCI group
Number of subjects: 176
Study 38911348 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg nicotine cigarettes
Number of subjects: 438
Study 38911477 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance training (HRT)
Number of subjects: 451
Study 38911477 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity training (MIT)
Number of subjects: 451
Study 38911477 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising control group (CON)
Number of subjects: 451
Study 38911519 — intervention group
Group type: EXPERIMENTAL
Intervention: HCM patients
Number of subjects: 60
Study 38911519 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 60
Study 38911552 — intervention group
Group type: EXPERIMENTAL
Intervention: AA plus TEA
Number of subjects: 66
Study 38911552 — intervention group
Group type: COMPARATOR
Intervention: AA plus sham TEA
Number of subjects: 66
Study 38911552 — intervention group
Group type: EXPERIMENTAL
Intervention: AA plus TEA and AA plus sham TEA
Number of subjects: 66
Study 38911584 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous PRP
Number of subjects: 32
Study 38911584 — intervention group
Group type: COMPARATOR
Intervention: steroid/anesthetic
Number of subjects: 32
Study 38911584 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 32
Study 38911647 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncardiac surgery
Number of subjects: 36657
Study 38911647 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer treatment in past 6 months
Number of subjects: 36657
Study 38911647 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate or on dialysis
Number of subjects: 36657
Study 38911647 — intervention group
Group type: EXPERIMENTAL
Intervention: General surgery
Number of subjects: 36657
Study 38911647 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke during index hospitalization
Number of subjects: 36657
Study 38911647 — intervention group
Group type: EXPERIMENTAL
Intervention: Discharge to nursing home
Number of subjects: 36657
Study 38911836 — intervention group
Group type: EXPERIMENTAL
Intervention: ActiveHip+ mHealth intervention
Number of subjects: 105
Study 38911836 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 105
Study 38911954 — intervention group
Group type: EXPERIMENTAL
Intervention: Affect labeling intervention
Number of subjects: 0
Study 38912192 — intervention group
Group type: EXPERIMENTAL
Intervention: Photopneumatic device
Number of subjects: 30
Study 38912228 — intervention group
Group type: EXPERIMENTAL
Intervention: ACS patients with high-CD4+ T cell trajectory
Number of subjects: 67
Study 38912228 — intervention group
Group type: COMPARATOR
Intervention: ACS patients
Number of subjects: 67
Study 38912228 — intervention group
Group type: COMPARATOR
Intervention: Chronic patients
Number of subjects: 67
Study 38912296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab (UST) therapy
Number of subjects: 52
Study 38912296 — intervention group
Group type: EXPERIMENTAL
Intervention: IUS parameters (B-mode, Doppler, dynamic CEUS, elastography)
Number of subjects: 52
Study 38912296 — intervention group
Group type: EXPERIMENTAL
Intervention: IUS score developed from ultrasound parameters
Number of subjects: 52
Study 38912588 — intervention group
Group type: EXPERIMENTAL
Intervention: Gbe1ys/ys mouse model
Number of subjects: 23
Study 38912588 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical and histopathology data from patients with GSD IV
Number of subjects: 23
Study 38912588 — intervention group
Group type: COMPARATOR
Intervention: Liver biopsy findings
Number of subjects: 23
Study 38912588 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmortem liver pathology analysis
Number of subjects: 23
Study 38912654 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirzepatide (10 mg or 15 mg)
Number of subjects: 0
Study 38912654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38912692 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored aggressive hydration (TAH) - 20 mL/kg bolus post-ERCP and 3 mL/kg/hr during and after ERCP
Number of subjects: 344
Study 38912692 — intervention group
Group type: COMPARATOR
Intervention: Tailored standard hydration (TSH) - 1.5 mL/kg/hr lactated Ringer's solution during and after ERCP
Number of subjects: 344
Study 38912692 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups assessed for elevated serum amylase levels and pain 4-6 hours after ERCP
Number of subjects: 344
Study 38912697 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid endoscopic submucosal dissection (H-ESD)
Number of subjects: 89
Study 38912697 — intervention group
Group type: COMPARATOR
Intervention: Conventional endoscopic submucosal dissection (C-ESD)
Number of subjects: 89
Study 38912784 — intervention group
Group type: EXPERIMENTAL
Intervention: Laminoplasty (LP)
Number of subjects: 163
Study 38912784 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior cervical decompression/fusion (ACDF)
Number of subjects: 163
Study 38912784 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior cervical decompression/fusion (PCDF)
Number of subjects: 163
Study 38912784 — intervention group
Group type: COMPARATOR
Intervention: PCDF
Number of subjects: 163
Study 38912784 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all surgical approaches)
Number of subjects: 163
Study 38912887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexaspline pulsed field ablation (PFA) catheter, delivering pulse intensities at PV ostium (1800 V) and atrium (2000 V)
Number of subjects: 143
Study 38912887 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexaspline pulsed field ablation (PFA) catheter
Number of subjects: 143
Study 38912884 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% human albumin solution (HAS)
Number of subjects: 301
Study 38912884 — intervention group
Group type: COMPARATOR
Intervention: Balanced crystalloid
Number of subjects: 301
Study 38912905 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with high triglyceride to total cholesterol (TG/TC) ratio
Number of subjects: 0
Study 38912905 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum TG/TC, TG/HDL and TG/LDL ratios
Number of subjects: 0
Study 38912927 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) therapy
Number of subjects: 40
Study 38913003 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 1145
Study 38913003 — intervention group
Group type: COMPARATOR
Intervention: Semaglutide
Number of subjects: 1145
Study 38913004 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2.4 mg
Number of subjects: 1145
Study 38913004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1145
Study 38913094 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive airway management
Number of subjects: 0
Study 38913094 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38913377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI
Number of subjects: 1639
Study 38913377 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided PCI
Number of subjects: 1639
Study 38913377 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular imaging-guided PCI with good glycemic control (HbA1c ≤7.5%)
Number of subjects: 1639
Study 38913539 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanreotide autogel/depot (120 mg every 28 days) plus best supportive care (BSC)
Number of subjects: 77
Study 38913539 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus best supportive care (BSC)
Number of subjects: 77
Study 38913574 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir (200 mg on day 1; 100 mg daily up to day 5)
Number of subjects: 243
Study 38913574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study 38913574 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir
Number of subjects: 243
Study 38913625 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app intervention for mental health promotion
Number of subjects: 60
Study 38913625 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 60
Study 38913710 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS IV 2.5 mg/kg
Number of subjects: 124
Study 38913710 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS IV 5 mg/kg
Number of subjects: 124
Study 38913710 — intervention group
Group type: EXPERIMENTAL
Intervention: VRC07-523LS IV 20 mg/kg
Number of subjects: 124